PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 33875937-0 2021 YM155 inhibits retinal pigment epithelium cell survival through EGFR/MAPK signaling pathway. YM 155 0-5 epidermal growth factor receptor Homo sapiens 64-68 33875937-10 2021 YM155 down-regulated total EGFR and phosphorylated external signal-regulated protein kinase (ERK), and it up-regulated the phosphorylation of P38MAPK and c-Jun N-terminal kinase (JNK). YM 155 0-5 epidermal growth factor receptor Homo sapiens 27-31 33875937-11 2021 YM155 induced endocytosis of EGFR in ARPE-19 cell. YM 155 0-5 epidermal growth factor receptor Homo sapiens 29-33 33875937-13 2021 Moreover, YM155 significantly decreased the expression of phosphorylated EGFR and ERK after treated by EGF. YM 155 10-15 epidermal growth factor receptor Homo sapiens 73-77 33875937-14 2021 CONCLUSION: YM155 inhibits RPE cell survival, the cell proliferative and migrative capacity, and it effectuates a small amount of cell death through the EGFR/MAPK signaling pathway. YM 155 12-17 epidermal growth factor receptor Homo sapiens 153-157 29413056-11 2018 Our results suggested that YM155, an ILF3 inhibitor, has the potential for utilization in cancer therapy against EGFR-positive lung cancers. YM 155 27-32 epidermal growth factor receptor Homo sapiens 113-117 32638093-1 2020 PURPOSE: This phase I study was conducted to evaluate the safety and pharmacokinetics of YM155, a potent, selective survivin inhibitor, in combination with erlotinib in patients with EGFR TKI refractory advanced non-small cell lung cancer (NSCLC). YM 155 89-94 epidermal growth factor receptor Homo sapiens 183-187 32001757-5 2020 We found that YM155 reduces EGFR expression in TNBC cells, shedding light on its potential mechanism of synergism with afatinib. YM 155 14-19 epidermal growth factor receptor Homo sapiens 28-32 30315932-0 2018 YM155 sensitizes non-small cell lung cancer cells to EGFR-tyrosine kinase inhibitors through the mechanism of autophagy induction. YM 155 0-5 epidermal growth factor receptor Homo sapiens 53-57 30315932-4 2018 In this study, we showed that YM155 markedly enhanced the sensitivity of erlotinib to EGFR-TKI resistant NSCLC cell lines H1650 (EGFR exon 19 deletion and PTEN loss) and A549 (EGFR wild type and KRAS mutation) through inducing autophagy-dependent apoptosis and autophagic cell death. YM 155 30-35 epidermal growth factor receptor Homo sapiens 86-90 30315932-4 2018 In this study, we showed that YM155 markedly enhanced the sensitivity of erlotinib to EGFR-TKI resistant NSCLC cell lines H1650 (EGFR exon 19 deletion and PTEN loss) and A549 (EGFR wild type and KRAS mutation) through inducing autophagy-dependent apoptosis and autophagic cell death. YM 155 30-35 epidermal growth factor receptor Homo sapiens 129-133 30315932-4 2018 In this study, we showed that YM155 markedly enhanced the sensitivity of erlotinib to EGFR-TKI resistant NSCLC cell lines H1650 (EGFR exon 19 deletion and PTEN loss) and A549 (EGFR wild type and KRAS mutation) through inducing autophagy-dependent apoptosis and autophagic cell death. YM 155 30-35 epidermal growth factor receptor Homo sapiens 129-133 30315932-10 2018 Therefore, combination of YM155 and erlotinib offers a promising therapeutic strategy in NSCLC with EGFR-TKI resistant phenotype. YM 155 26-31 epidermal growth factor receptor Homo sapiens 100-104 28787001-0 2017 YM155 as an inhibitor of cancer stemness simultaneously inhibits autophosphorylation of epidermal growth factor receptor and G9a-mediated stemness in lung cancer cells. YM 155 0-5 epidermal growth factor receptor Homo sapiens 88-120 28787001-8 2017 Notably, YM155 inhibited tumorsphere formation by blocking the autophosphorylation of EGFR and the EGFR-G9a-mediated stemness pathway. YM 155 9-14 epidermal growth factor receptor Homo sapiens 86-90 28787001-8 2017 Notably, YM155 inhibited tumorsphere formation by blocking the autophosphorylation of EGFR and the EGFR-G9a-mediated stemness pathway. YM 155 9-14 epidermal growth factor receptor Homo sapiens 99-103 23325792-0 2013 YM-155 potentiates the effect of ABT-737 in malignant human glioma cells via survivin and Mcl-1 downregulation in an EGFR-dependent context. YM 155 0-6 epidermal growth factor receptor Homo sapiens 117-121 23325792-11 2013 As with YM-155 alone, sensitivity to YM-155 and ABT-737 inversely correlated with EGFR activation status. YM 155 8-14 epidermal growth factor receptor Homo sapiens 82-86 23325792-11 2013 As with YM-155 alone, sensitivity to YM-155 and ABT-737 inversely correlated with EGFR activation status. YM 155 37-43 epidermal growth factor receptor Homo sapiens 82-86 22723871-0 2012 YM155 induces EGFR suppression in pancreatic cancer cells. YM 155 0-5 epidermal growth factor receptor Homo sapiens 14-18